Kornimate/medical-research-clean huggingface dataset:
evaluation of the reversibility of the bronchial obstruction by impulse oscillometry technique in chronic obstructive pulmonary disease (copd): correlation with functional features measured by plethysmography and dyspnoea

Conditions: COPD

Summary: limitation of expiratory flows is considered as the main determiner of dynamic distension and dyspnoea in chronic obstructive pulmonary disease (copd). the analysis of proximal and distal resistances should allow to better appreciate the functional impact. this study should also allow to specify the best parameters in respiratory functional explorations useful for the follow-up in copd and to specify the relevance of functional indications other than the forced expiration volume at 1 second (fev1) or the functional residual capacity (frc) to estimate in a more relevant way the clinical improve with the increase of the therapeutic load (increase of posology, association of two bronchodilatators, addition of an anti-inflammatory drug, thus etc...) at already handled patients suffering from a persistent dyspnoea insufficiently relieved.


Eligibility criteria:
inclusion criteria: * copd with dyspnoea with medical research council scale (mrc) \>1, * no exacerbation for 6 weeks * no bronchodilatator short action(share) (ß 2 agonist or ipratropium) within 6 hours before the respiratory evaluation and the test of reversibility. * patient under current treatment (ß2 long-acting agonist (laba) or anticholinergic long-acting (llama(lama)) or laba-corticoid association inhaled (csi), or triples laba-csi-lama association) stable for at least 4 weeks, and taken for at least the 1 hour the day of the visit * having given a written consent exclusion criteria: * patient under 18 * other respiratory illness * clinically significant left cardiac failure * obesity with bmi \> 35 kg / m2) * unable to perform respiratory evaluations * contraindication to the salbutamol or to the ipratropium bromide or to one of its components * pregnant or breast-feeding woman * unable to agree * no social security scheme

Keywords: resistance forced oscillations dyspnea
combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Conditions: Sensitivity

Summary: combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma


Eligibility criteria:
inclusion criteria: * 1. aged between 18 and 75 years; * 2. lung adenocarcinoma; * 3. the patient is able to receive neoadjuvant pemetrexed and cisplatin chemotherapy * 4 .the patient is able to understand and comply with the study and has provided written informed consent. exclusion criteria: * 1. patients with a history of lung surgery; * 2. postoperative pathology showed non-primary lung cancer; * 3. patients with a history of other tumors; * 4. patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis); * 5. unable to cooperate with the researchers because of dementia or cognitive decline * 6. other situations that are not in conformity with the standards and requirements of this trial.
clinical trial phase i for theragene in combination with chemotherapy for the locally advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: pancreatic cancer is associated with an extremely poor prognosis, reflected by a 5-y survival probability of less than 5% when all stages are combined. at present, only approximately 10%-20% of patients are considered candidates for curative resection. the majority of patients (50%-60%) are present with metastatic disease, and substantial number of patients (approximately 30%-40%) are considered ''locally advanced'' at the time of diagnosis. replication-competent adenovirus-mediated double suicide gene therapy (theragene®,ad5-ycd/muttksr39rep-adp) showed an anti-cancer effect in patients with prostatic cancer in phase i study. from the experience of prostatic cancer, the safety of combination with standard chemotherapy with theragene treatment is assessed in this study.


Eligibility criteria:
inclusion criteria: * patients with pancreatic cancer stage 3 * patients with histologically confirmed pancreatic adenocarcinoma * patients with no evidence of peritoneal or hematogenous metastasis * patients with ecog performance status 0-2 * patients with renal function (serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 50 ml/min/m²) * patients with bone marrow function (wbc \> 4,000/ul or absolute neutrophil count ≥ 1500/ul, plt ≥ 100,000/ul, and hemoglobin \> 10 g/dl) * patients with liver function (bilirubin \< 2.0 mg/dl and sgot and sgpt \< 2.5 times upper limit of normal (uln)) * patients with agreement with informed consent * male patients with contraception exclusion criteria: * female patients with childbearing age or pregnancy or breast feeding * patients with a history of chemotherapy within 5 years * patients with a history of radiation on more than 25% of bone marrow * patients with unknown stage or recurrent pancreatic cancer * patients with a history of skin cancer except malignant melanoma or malignancy except stage 0 cervical cancer * patients with a history of major surgery except laparoscopic exam, endoscopic ultrasound, stenting, or peg/pej placement * patients with active or uncontrolled infection * patients with immunosuppression or susceptibility to viral infection * patients with hiv infection, chronic hepatitis b, chronic hepatitis c, or liver cirrhosis * patients with a history of allergy to clinical trial medications * patients who are considered as inappropriate candidate by investigators

Keywords: pancreatic cancer adenovirus gene therapy
digitally assisted recovery coach

Conditions: Alcohol Use Disorder; Alcohol Withdrawal

Summary: the aims of this proof-of-concept study are to determine the feasibility of 1) using a smartphone app ("lifeguard") to facilitate engagement with a peer recovery coach, 2) monitoring post-detox using a modified brief addiction monitor, and 3) assessing linkage to care post-detox.


Eligibility criteria:
inclusion criteria: * adults aged 18 to 65 * diagnosis of dsm-5 alcohol use disorder * admitted to brigham and women's faulkner hospital (bwf) inpatient addiction recovery program to treat alcohol withdrawal * own either an ios or android smartphone device * have an active email address * english speaking exclusion criteria: * inability to provide informed consent due to delirium or other cognitive impairments * current psychosis, suicidality or homicidality

Keywords: alcohol use disorder peer recovery coach smartphone app
human leukocyte antigen (hla) - a*2402 restricted peptide vaccine therapy in patients with advanced esophageal cancer

Conditions: Esophageal Cancer

Summary: the purpose of this study it to evaluate the safety and immune response of peptides (urlc10) emulsified with montanide isa51 in treating patients with unresectable, advanced or recurrent esophageal cancer.

urlc10 have been identified as cancer specific molecules especially in non small cell lung cancer using genome-wide expression profile analysis by cdna microarray technique. in a prior study, it has been shown that urlc10 are upregulated in human esophageal tumors. the investigators identified that peptides derived from these proteins significantly induce the effective tumor specific ctl response in vitro. according to these findings, in this trial, we evaluate the safety, immunological and clinical response of urlc10 peptide. patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. on each vaccination day, the urlc10 peptide (1mg) mixed with montanide isa 51 will be administered by endodermic injection

Eligibility criteria:
inclusion criteria: 1. patients must have advanced or recurrent esophageal cancer, and treatment has failed, or in the situation where effective therapy is not available, or has been refused due to severe adverse effects of chemotherapy 2. who performance status of 0 to 2 3. age ≥ 20 years, ≤80 years 4. the patient does not need to have a measurable disease, but must have a disease that an effect judgment is possible 5. passing from previous treatment more than two weeks. passing from radiation therapy more than four weeks. 6. expected survival of at least 3 months 7. wbc≥ 1,500/mm³ wbc≤ 15,000/mm³ platelet count ≥ 50,000/mm³ total bilirubin ≤ 3 x the institutional normal upper limits ast, alt ≤ 3 x the institutional normal upper limits creatinine ≤ 3 x the institutional normal upper limits 8. patients must be hla-a2402 9. able and willing to give valid written informed consent exclusion criteria: 1. pregnancy, promise of the pregnancy, hope of the pregnancy, breastfeeding 2. serious infections requiring antibiotics 3. concurrent treatment with steroids or immunosuppressing agent 4. disease to the central nervous system 5. decision of unsuitableness by principal investigator or physician-in-charge

Keywords: peptide vaccine urlc10
specifying the anti-inflammatory effects of ziltivekimab

Conditions: Atherosclerosis; Inflammation

Summary: the goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.

considering that ziltivekimab is currently undergoing a phase 3 cvot trial, it is of great importance to elucidate its mechanistic effects. the objective of this study is to research whether ziltivekimab therapy for 20 weeks reduces arterial wall inflammation, as assessed by state-of-the-art imaging modalities, and reduces systemic inflammatory tone, as assessed by in depth phenotyping of circulating monocytes, inflammatory biomarkers and proteomics. the imaging modalities used in this study are 68ga-dotatate pet/ct and ccta. this study is designed as a single center, randomized, double-blinded, placebo-controlled intervention study in 40 atherosclerotic patients of 50 years and older with hscrp levels of 2 mg/l and above.

Eligibility criteria:
inclusion criteria: * aged 50 years and older. * multi-vessel coronary artery disease (defined as cad-rads ≥2). * serum hscrp level ≥2 mg/l. exclusion criteria: * coronary stents in situ. * chronic or recent (\<1 month) (serious) infections and/or clinical signs of acute (serious) infection. * history of severe auto-immune diseases, or other (severe) (recurrent or chronic) inflammatory disorders. * use of preventive systemic antibiotics (antibiotics used to treat latent tuberculosis are exempted). * stable lipid lowering treatment for less than 4 weeks, including statins, ezetimibe and pcsk9 inhibition. * untreated latent tuberculosis, active hepatitis b (positive hbsag and/or positive anti-hbc with detectable hbv dna) or c, human immunodeficiency virus (hiv) not on stable antiretroviral regimen * uncontrolled diabetes (hba1c \>90 mmol/mol). * renal insufficiency, defined as egfr \<45 ml/min/1.73 m2. * platelet count \ 450,000 /mm3. * elevated liver enzymes (\>3 uln of liver transaminases), acute liver failure or known (severe) liver disease. * premenopausal women not using birth-control. * history of gastrointestinal perforation, active diverticulitis (within 5 years) or active inflammatory bowel disease (within 12 months). * uncontrolled hypertension (systolic \>180 mmhg; diastolic \>110 mmhg). * diagnosis of (active) malignancy in last 5 years. * standard contra-indications to 68ga-dotatate pet, and ct based on physician's experience and current practices. * inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.

Keywords: dotatate ziltivekimab inflammation monocytes ccta pet/ct
supporting lifestyle changes after delivery

Conditions: Obesity, Maternal; Lifestyle

Summary: use of information and communication technology -based health behavior change support system in modifying lifestyle after delivery among women with obesity.

postpartum weight retention is common and particular when accompanied with prior obesity, it further increases the risks of subsequent pregnancies and adverse effects on the long-term health. the aim of this randomized controlled trial is to examine whether using an information and communication technology (ict) -based health behavior change support system (hbcss) reduce postpartum weight retention and disorders related to subsequent pregnancy. web-based hbcss application utilizes persuasive design and cognitive behavioral therapy. 200 participants with prepregnancy obesity (bmi ≥ 30.0 kg/m\^2) and age ≥ 18 years are randomly assigned into two groups after delivery in the oulu university hospital. the study period begins 5-12 weeks after delivery. all participants will have conventional postpartum lifestyle counselling and the intervention group get in addition access for 12 months to web-based hbcss application, which is recommended to use twice a week for 5-10 minutes. participants are followed by questionnaires up to 24 months. the main outcome is weight change from baseline to 12 and 24 months. medical records and national registers are used for long-term follow-up. researchers have permission to contact participants afterwards. the ethical approval is permitted by the regional medical research ethics committee of the wellbeing services county of north ostrobothnia. the authorization for the use of medical device is granted from the finnish medicines agency. recruitment of the participants will be performed 2/2024-1/2026.

Eligibility criteria:
inclusion criteria: * pre-pregnancy bmi ≥ 30.0 kg/m\^2 * smartphone user exclusion criteria: * eating disorder * severe mental disorder * use of other lifestyle support system or medication * non-finnish speaker
obesity-related inflammation in patients prior to and after bariatric surgery

Conditions: Obesity; Morbid Obesity

Summary: this study investigates the chronic long-term health condition of obesity and its effect on neutrophil function and the inflammatory response

inflammation is a central component of the immune response. in its acute form it aids the transition from disease to health via the activation of numerous immune cells, enabling them to reach the site of infection/injury and orchestrate themselves to combat pathogens, facilitating resolution and repair to restore the host to health. however, chronic inflammation is deleterious to the host and differs from the "classical" acute inflammatory process in that the inflammation is not necessarily so readily obvious and is not self-limiting; rather, the immune system is in a constant state of low-grade activation and when challenged by pathogenic or sterile injury the response is heightened, resulting in prolonged tissue damage and a failure of efficient resolution mechanisms. neutrophils are important mediators of acquired innate immune responses but may also contribute to the pathogenesis of chronic inflammatory diseases. neutrophils are heavily involved in antimicrobial defence; their primary role is the localisation and elimination of pathogenic microorganisms. this, combined with their relatively short lifespan, has resulted in a traditional view of them as limited "kamikaze" cells. however, as detailed here, neutrophils have been shown to act with complexity and sophistication, orchestrating the immune/inflammatory response but also inadvertently contributing to tissue damage in different disease states. this study investigates the chronic long-term health condition of obesity and its effect on neutrophil function and the inflammatory response

Eligibility criteria:
inclusion criteria for bariatric participants: * bmi \>40 * undergoing gastric band surgery exclusion bariatric participants criteria: * undergoing alternative weight loss surgery * bmi\<40 * smoking * pregnancy exclusion criteria for the controls * bmi over 27 * pregnancy * smoking * evidence of systemic disease * use of medications/vitamin supplements.

Keywords: gastric bypass obesity morbid obesity matched healthy controls
bipolar plasmakinetic turp vs monopolar turp in the treatment of lower urinary tract symptoms

Conditions: Prostatic Hyperplasia; Lower Urinary Tract Symptoms; Transurethral Resection of Prostate

Summary: randomized controlled trial with one-year follow-up comparing intra, peri and postoperative outcomes for plasmakinetic transurethral resection of prostate (pk-turp) and monopolar transurethral resection of prostate (m-turp) in the treatment of luts due to bph in a tertiary-care public institution

the study is a randomized controlled trial with one-year follow-up comparing intra, peri and postoperative outcomes (efficacy, complications and sequelae) for plasmakinetic transurethral resection of prostate (pk-turp) and monopolar transurethral resection of prostate (m-turp) in the treatment of luts due to bph in a tertiary-care public institution (madrid, spain)

Eligibility criteria:
inclusion criteria: * sign the informed consent voluntarily and will be willing to follow-up * prostate volume \<80 g * meet any conditions (1) diagnose of luts due to refractory to drugs bph. (2) presenting complications derived from bph (bladder calculi, recurrent haematuria, recurrent urinary tract infections, acute urinary retention) * the use of antiplatelet agents or anticoagulant drugs is allowed. exclusion criteria: * previous history of pelvic surgery * previous history of pelvic radiotherapy * previous history of neurogenic bladder dysfunction * documented or suspected prostate carcinoma * patients with severe cardiopulmonary disease or severe mental disorders * poor compliance, and can not be followed up.
optical coherence pachymetry to evaluate central corneal ablation depth in myopic femtosecond laser in situ keratomileusis

Conditions: Myopia

Summary: prospective study aiming to measure central ablation depth during excimer laser surgery in myopic patients operated with femtosecond laser assisted lasik with intraoperative ocp, before and after laser ablation. this measurement will be compared with pre and 1 month postoperative topography differential pachymetric measurements.


Eligibility criteria:
inclusion criteria: * patients over 18 years old * undergoing refractive surgery with lasik * with myopic or compound myopic astigmatism ametropia * without irregular cornea and topographical sign of keratoconus * preoperative corneal thickness compatible with lasik exclusion criteria: * hyperopia * opposition to participate in the study * no health insurance coverage * patient under legal protection * pregnant or breastfeeding patient
nailfold capillary blood flow with latanoprost bunod

Conditions: Glaucoma, Open-Angle

Summary: the purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. nailfold capillaroscopy (nfc) is a video camera with a magnifying lens used for studying the movement of blood in small blood vessels. it is simple, safe and does not penetrate the skin. the skin fold that is at the tip of the finger is called the "nailfold". nfc has been used to assess blood vessel narrowing in patients with glaucoma.

in this study, the study team investigates the effect of topically-applied latanoprostene bunod (ltb) on the blood flow at the nailfold of the 4th finger in patients with primary open angle glaucoma. ltb is a new anti-glaucoma eye drop which received fda clearance in early november 2017. it has two components: the prostaglandin analog (pga) which decreases intraocular pressure (iop) by enhancing the drainage of the aqueous (the fluid in the front part of the eye) from the eye, and the nitric oxide (no) moiety which naturally dilates arteries in the body. the capillaries at the nailfold are comparable to those of the optic nerve head, which makes them a reasonable surrogate for evaluation of the effect of ltb on the blood flow. therefore, this study may provide indirect evidence for the beneficial effect of ltb on blood flow to optic nerve which can potentially save the optic nerve from glaucomatous damage. primary open angle glaucoma is a progressive condition and is the most common cause of irreversible blindness worldwide. primary open angle glaucoma (poag) is a subset of the glaucomas defined by an open, normal appearing anterior chamber angle and raised intraocular pressure (iop), with no other underlying disease. in addition to ltb, the study team will use latanoprost (l), an-fda approved pga anti-glaucoma eye drop and normal saline (ns: the physiologic solution composed of 0.9% salt and water), as controls to make sure the effects of lpb on nail fold capillary blood flow is not due to its pga (as l is) or due to the placebo effect (as ns is). this study may also serve as background information for the development of new anti-glaucoma medications which can be injected into the eye to facilitate blood flow to the optic nerve.

Eligibility criteria:
inclusion criteria: * 40 years old to 80 years old * all participants will have open angles and no signs of secondary glaucoma such as exfoliation syndrome * untreated intraocular pressure (iop) may be ≤ 21mmhg or ≥ 21mmhg in both eyes * the cup-to-disc ratio (cdr) ≥ 0.6 in both eyes and cdr asymmetry ≤ 0.2. * poag patients will have reliable humphrey visual field (hvf) loss consistent with optic nerve damage * poag patients can have any stage of poag and be on any form of treatment for their disease. * willingness to sign informed consent and comply with study procedures. exclusion criteria: * history of non-poag forms of glaucoma * pregnancy * inability to give informed consent

Keywords: nailfold capillary imaging latanoprost bunod latanoprost